IntoCell Inc banner

Valor intrínseco

No disponible para IntoCell Inc

No hay suficientes datos para calcular de forma fiable el valor intrínseco de IntoCell Inc.

¿Nuestras valoraciones funcionan de verdad? Ver resultados del backtest .

Alternativas a IntoCell Inc

Análisis fundamental

Qué hace IntoCell

Biotecnología Health Care

IntoCell, Inc. engages in the research and development of ADC platform technology. The company is headquartered in Daejeon, Daejeon and currently employs 43 full-time employees. The company went IPO on 2025-05-23. The firm mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.

Sede central
Corea KR
Empleados
43
Fecha de salida a bolsa
23 may., 2025
Leer el resumen completo de la empresa
Ver resumen de la empresa
Finanzas

Desglose de ingresos y gastos
IntoCell Inc

Eficiencia

Cascada de ganancias
IntoCell Inc

Precios objetivo de Wall St

Retornos de capital

Rentabilidad por recompra de acciones
BLOQUEADO
Rentabilidad por reducción de deuda
BLOQUEADO

Panorama competitivo